A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification
Estelle Verburgh(Groote Schuur Hospital), G. Verhoef(TiGenix (Spain)), Ruth Achten(Jessa Hospital), Peter Vandenberghe(KU Leuven), Caroline Brusselmans(KU Leuven), Michel Delforge(KU Leuven), A Hagemeijer(KU Leuven), M. Boogaerts(KU Leuven), Vernon Louw(University of Cape Town)
Cited by 66
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695